Pending actions
2
Historical total
2
Resolved / remanded
0
Newly Centralized. Consolidated within the last 18 months. Of 2 lawsuits ever part of this litigation, 2 remain active.
About this litigation
Respimat Pharmaceuticals Antitrust Litigation is a federal multidistrict litigation classified by the Judicial Panel on Multidistrict Litigation as a Antitrust docket. It was centralized on August 7, 2025 before Denise J. Casper, Chief Judge, USDC, in the D. Massachusetts.
As of the August 3, 2026 JPML report, 2 individual lawsuits are pending in this MDL. Cases coordinated in an MDL keep their separate identity — they are managed together only for pretrial proceedings. Learn how MDLs work.
Related Antitrust MDLs
View categoryMultiPlan Health Insurance Provider Litigation
150
pending actions
MDL 3121
N.D. Illinois
Generic Pharmaceuticals Pricing Antitrust Litigation
144
pending actions
MDL 2724
E.D. Pennsylvania
Domestic Airline Travel Antitrust Litigation
105
pending actions
MDL 2656
D. District of Columbia
Payment Card Interchange Fee and Merchant Discount Antitrust Litigation
65
pending actions
MDL 1720
E.D. New York